No Reorganization Ahead, but Uncertainty Remains Around Staffing and CDER's Ombudsman
Through our Venable FDA Pulse series, we report on critical developments within the Food and Drug Administration (FDA or Agency) that may affect the Agency's structure and stakeholder interactions. This week, we discuss four key updates:
- The latest FDA leadership changes
- FDA Commissioner Makary confirms that FDA will not undergo reorganization
- Rehiring efforts following staff terminations and
- Uncertainty around the Center for Drug Evaluation and Research (CDER) Office of the Ombudsman
Recent FDA Leadership Changes
On May 6, 2025, Commissioner Makary announced via the social media platform X that Dr. Vinay Prasad will be the next director of the Center for Biologics Evaluation and Research, succeeding Dr. Peter Marks, who resigned from FDA in April. Additionally, Politico reported that Jeremy Walsh will serve as the Agency's inaugural chief artificial intelligence (AI) officer. While FDA welcomed these new leaders, it was reported that Michael Rogers, the associate commissioner for inspections and investigations, will retire from the Agency. Rogers' departure comes as FDA plans to increase unannounced inspections at foreign manufacturing facilities that make food, essential medicines, and other medical products for U.S. consumers and patients.
Update: Commissioner Makary Confirms That FDA Will Not Be Reorganized
As we previously discussed in our 100-day review of the second Trump administration, it was reported that HHS had considered a plan to reorganize FDA into five or six offices by combining similar activities of the centers, such as product reviews, policy, and inspections, into single offices. However, on April 29, 2025, Commissioner Marty Makary stated in an interview with MedPage Today that FDA will not be reorganized. Instead, FDA plans to consolidate information technology and travel offices, as well as "other things that make sense for efficiency." Dr. Makary mentioned that a reorganization plan for FDA had been proposed, but that he rejected it.
Rehiring of Some FDA Staff
Dr. Makary's confirmation provides relief to those concerned about how the plan might have affected FDA's ability to review regulated products, especially considering that the Agency recently lost a significant number of staff because of workforce reduction. Relatedly, it was reported that FDA will rehire some employees who were fired during the April workforce reduction or has asked them to return, including food safety scientists, those who make travel arrangements for safety inspectors, employees who handled Freedom of Information Act requests, and user fee negotiation personnel.
CDER Ombudsman in Limbo: What This Means for Drug Application Reviews
CDER's Office of the Ombudsman, which investigates complaints and resolves disputes between CDER and stakeholders, may be closed. However, it is unclear whether this closure will be permanent or temporary. On April 18, 2025, Bloomberg Law reported receiving an automated email from the office stating that its "services are currently unavailable" and recommending that the recipient contact the office again in May, when it anticipates having additional information. According to the report, a source confirmed that staff in the Office of the Ombudsman were included in the staffing cuts at FDA. Additionally, the news outlet received another automated email stating that Virginia Behr, the CDER ombudsman, retired on April 10, 2025.
At this time, there has been no update on the status of the CDER Ombudsman's office or whether operations have resumed since the news was first reported. The potential closure of the Ombudsman's office would be impactful, as the office served as a key resource for efficiently, quickly, and informally resolving regulatory, scientific, and administrative disputes that may arise during the drug review process.
Venable will continue to monitor all changes regarding FDA and report any critical developments. If you have questions on how the contents of this article may impact you or your business's interactions with FDA, please contact the authors today.
FDA at the 100-Day Mark of Trump Administration 2.0
Since returning to office for a second term, President Trump has taken steps to reshape federal agencies. Here, we discuss the significant changes that have occurred at the Food and Drug Administration (FDA or Agency) during the first 100 days of the second Trump administration, including (1) the appointment of a new commissioner; (2) changes in FDA leadership; and (3) plans to reorganize the Agency and reduce its workforce.
New FDA Commissioner
On March 25, 2025, Martin "Marty" Makary was confirmed by the Senate to be the 27th Commissioner of Food and Drugs (FDA commissioner). Former Acting Commissioner Sara Brenner will serve as principal deputy commissioner.
In remarks given during a welcome ceremony at FDA headquarters, Makary stated his goal is "to ensure that the FDA holds to the gold standard of trusted science, transparency, and common sense to rebuild public trust and advance health and safety in the United States and worldwide." Makary mentioned an array of different topics, including the "chronic disease epidemic," obesity, and autism, without announcing specific policy prescriptions. Makary discussed the need for people "with a range of perspectives and critical thinkers to respond following the scientific method and using common sense." Commissioner Makary will speak at the 2025 Food and Drug Law Institute (FDLI) Annual Conference on May 15, as well as Robert Foster, the U.S. Department of Health and Human Services (HHS) deputy general counsel and chief counsel for food, research, and drugs. The position of chief counsel for food, research, and drugs was created as part of the reorganization of HHS's office of the general counsel and supervises FDA's chief counsel.
As Makary's tenure progresses, we will be monitoring how he brings his vision for FDA into action.
FDA Leadership Changes
As Commissioner Makary began his tenure, FDA experienced layoffs, resignations, and retirements, all of which are ushering in a new regulatory environment for drugs, devices, and other regulated products. Below is the current state of FDA leadership as of April 28, 2025:
- Center for Devices and Radiological Health (CDRH)
- Michelle E. Tarver, Director
- Center for Drug Evaluation and Research (CDER)
- Jacqueline Corrigan-Curay, Acting Director
- Center for Biologics Evaluation and Research (CBER)
- Scott Steele, Acting Director (replaced Peter Marks, who resigned earlier this month)
- Center for Tobacco Products (CTP)
- Vacant, Director (previously held by Brian King, who was placed on administrative leave earlier this month)
- Human Foods Program
- Kyle Diamantas, Acting Deputy Commissioner for Human Foods (replaced James "Jim" Jones, who resigned in February 2025)
Additionally, it was reported that Makary made the following appointments last week as part of his efforts to finalize his team:
- Center for Veterinary Medicine (CVM)
- Timothy Schell, Acting Director
- Craig Taylor, Acting Chief Information Officer (replaced Vid Desai, who was placed on administrative leave earlier this month)
- Lowell Zeta, Deputy Commissioner for Strategic Initiatives
Additional leadership positions remain vacant as of April 28, 2025, including chief counsel and chief medical officer.
Implications of Staffing Cuts, Proposed Agency Restructuring, and Budget Changes
In April, HHS began implementing plans to reduce its workforce, which, according to a fact sheet, will result in FDA losing "approximately 3,500 full-time employees." The fact sheet states that the cuts "focus on streamlining operations and centralizing administrative functions" and "will not affect drug, medical device, or food reviewers, nor will [they] impact inspectors." These cuts follow an earlier round of terminations that occurred in February. Notably, there have been reports that FDA has rehired or reinstated some fired personnel, suggesting that cuts may have been made to positions that the Agency later determined were necessary.
Return-to-office orders could further reduce FDA's workforce along with the planned staffing cuts. Employees living outside a 50-mile radius of FDA's headquarters are to report in person starting April 28, potentially leading to attrition. Moreover, according to reports, HHS has considered a plan to restructure FDA into five or six offices, by merging similar activities of the centers, such as product reviews, policy, and inspections, into single offices. Additionally, news outlets have reported on a leaked HHS budget document that proposes significantly reducing FDA's overall funding but allocates adequate funding to maintain the user fee programs.
Although Makary has struck a positive tone so far, the combination of staffing cuts, a smaller budget, and a reorganization of the Agency could impact FDA's ability to review regulated products. Several PDUFA decision dates are pending in the next few weeks that may provide insight into FDA's current ability to meet target deadlines. Additionally, there are reports that FDA is planning to end most of its routine food inspections work, which would be outsourced to state and local authorities. Meanwhile, FDA recently announced its plan to phase out petroleum-based synthetic dyes from the U.S. food supply. Further, the Agency is continuing to work to educate stakeholders about the updated "healthy" nutrient content claim rule, which went into effect April 28, by publishing a pre-recorded webinar that outlines the rule.
Venable will continue to monitor all changes regarding FDA and report any critical developments. If you have questions on how the contents of this article may impact you or your business's interactions with FDA, please contact the authors today.